Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)


Facebook
        Twitter
        LinkedIn
        Syndicate





ACIP Evidence to Recommendations for Use of JYNNEOS (orthopoxvirus) Vaccine Heterologous for Those Who Received ACAM2000 Primary Series (Policy Question 5)										Related Pages
										**Question****:**Should persons who are at continued risk* for occupational exposure to orthopoxviruses, and who received an ACAM2000 primary vaccination, receive a booster dose of JYNNEOS as an option to a booster dose of ACAM2000?
**Population:** Persons who are at risk for occupational exposure to orthopoxviruses
**Intervention:** Booster with JYNNEOS
**Comparison(s):** Booster with ACAM2000
**Outcome:** 1) Prevention of disease 2) Severity of disease 3) Severe adverse events 4) Myo-/peri-carditis
*Orthopoxvirus and healthcare worker response teams designated by appropriate public health and antiterrorism authorities are not at “continued risk” because they are vaccinated for the purposes of preparedness.**Background:**
The ACIP recommends booster doses of ACAM2000 every 3 years for persons at occupational risk for virulent replicating orthopoxviruses (e.g., variola virus and monkeypox) and at least every 10 years for persons at occupational risk for less virulent orthopoxviruses (e.g., cowpox and vaccinia virus).  Vaccination with ACAM2000 has contraindications (e.g., being a household contact of a person with eczema), is believed to have more serious adverse events (including myopericarditis), and requires infection control measures because contact with the vaccination site can result in auto-inoculation or infection to others.  Additionally, the vaccination technique can be painful and a smaller number of providers are willing to administer it compared to subcutaneous vaccines like JYNNEOS.
CDC has received multiple inquiries from federal agencies, occupational health clinics, and vaccinees inquiring about when JYNNEOS will be available specifically because they would like to receive JYNNEOS (instead of ACAM2000) for booster vaccines even though they received ACAM2000 primary series.Problem
Problem
Criteria
Work Group Judgements
Evidence
Additional Information**Is the problem of public health importance?**
Yes
Health authorities are being asked when JYNNEOS will be available so that persons previously receiving ACAM2000 can switch to JYNNEOS.
Some laboratory directors have indicated that their entire lab will switch to JYNNEOS once it becomes available as long as the ACIP recommendations overtly allow for this.
There is unpublished data from DRC that JYNNEOS is preferred to ACAM2000; we anticipate there will be many requests in the U.S. for JYNNEOS as well.Benefits and Harms
Benefits and Harms
Criteria
Work Group Judgements
Evidence
Additional Information**How substantial are the desirable anticipated effects?**
Large
Logistics for receiving vaccine and maintaining the vaccine site are easier
Comparable “protection” to ACAM2000 presumed
JYNNEOS is not a live virus so there is no potential for spread to others
There are few contraindications**How substantial are the undesirable anticipated effects?**
Minimal
No known harms; however, the Evidence table could not adequately assess adverse events given the low number of subjects and other study limitations**Do the desirable effects outweigh the undesirable effects?**
Favors interventional
Benefits listed above are large and the harms are minimal**What is the overall certainty of this evidence for the critical outcomes?**
Effectiveness of the intervention:
Very low
The Evidence table shows very low certainty for every outcome pertaining to this PICO questionValues
Values
Criteria
Work Group Judgements
Evidence
Additional Information**Does the target population feel that the desirable effects are large relative to undesirable effects?**
Yes
There is no research data to evaluate this but the target population has been making multiple requests for this vaccine**Is there important uncertainty about or variability in how much people value the main outcomes?**
Probably not important uncertainty or variability
Although there is no research identified, stakeholders are expected to value persistent immunity
Employers are expected to favor the convenience of JYNNEOS vaccinations and some laboratory directors have indicated that their entire laboratory may be favor JYNNEOS if given the optionAcceptability
Acceptability
Criteria
Work Group Judgements
Evidence
Additional Information**Is the intervention acceptable to key stakeholders?**
Yes
Ease of difficulty finding provider
No risk of transmission to others
No absences from work to travel to a provider who can give the vaccine; any provider can administer a subcutaneous injection
Less pain and no concerns for auto-inoculation or infection transmission to others, particularly to immunocompromised persons and those with eczema
Although there is no research evidence available, orthopoxvirus recipients have repeatedly reached out to CDC and the product sponsor to ask about the availability of the vaccine suggesting that the convenience associated with the vaccine makes the booster dose acceptable.Resource Use
Resource Use
Criteria
Work Group Judgements
Evidence
Additional Information**Is the intervention a reasonable and efficient allocation of resources?**
Yes
JYNNEOS, like ACAM2000, would be provided from HHS’ Strategic National Stockpile (SNS) free-of-cost to the patient
The cost of the clinic appointment would be the same as that for ACAM2000 vaccinationEquity
Equity
Criteria
Work Group Judgements
Evidence
Additional Information**What would be the impact on health equity?**
Probably increasedt
For some vaccine recipients, the cost of the clinic appointment is absorbed by the employer; for others, it is not.  There would be no change in those costs.  However, there would be decreased costs and challenges for those who have to travel to identify a provider to provide the vaccine.Feasibility
Feasibility
Criteria
Work Group Judgements
Evidence
Additional Information**Is the intervention feasible to implement?**
Yes
No research identified
Same number of clinic visits as with ACAM2000Balance of consequences
Desirable consequences *probably outweigh*undesirable consequences in most settings
Is there sufficient information to move forward with a recommendation? Yes.
Policy options for ACIP consideration
ACIP recommends the intervention
Final deliberation and decision by the ACIP
Final ACIP recommendation
Additional ACIP considerations
Top of Page
							
					
						Page last reviewed:  May 25, 2022					Content source: 	National Center for Immunization and Respiratory Diseases homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue